Literature DB >> 29411540

Editorial: The American College of Rheumatology White Paper on Biosimilars: It Isn't All White-There Is Some Gray and Black.

Roy Fleischmann1,2.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29411540     DOI： 10.1002/art.40402

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN： 2326-5191            Impact factor:   10.995


× No keyword cloud information.
  4 in total

Review 1.  Focus on biosimilar etanercept - bioequivalence and interchangeability.

Authors:  Fabrizio Cantini; Maurizio Benucci
Journal:  Biologics       Date:  2018-08-30

2.  Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis.

Authors:  Bente Glintborg; Rikke Ibsen; Rebecca Elisabeth Qwist Bilbo; Merete Lund Hetland; Jakob Kjellberg
Journal:  RMD Open       Date:  2019-08-12

3.  Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018.

Authors:  Yifei Liu; Martha Skup; Min Yang; Cynthia Z Qi; Eric Q Wu
Journal:  Adv Ther       Date:  2022-06-23       Impact factor: 4.070

4.  Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis.

Authors:  Bente Glintborg; Jan Sørensen; Merete Lund Hetland
Journal:  RMD Open       Date:  2018-07-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.